CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED) - USD ($) $ in Millions		Total	Common Stock		Treasury Stock		Treasury Stock Share Repurchase Program	[3]	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Equity Attributable to Noncontrolling Interests
Beginning balance (in shares) at Dec. 31, 2020	[1]		501,900,000
Beginning balance at Dec. 31, 2020		$ 3,773	$ 5		$ (2,230)				$ 1,065	$ 5,659	$ (730)	$ 4
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest		1,069								1,071		(2)
Other comprehensive income/(loss), net of tax		107									107
Treasury stock, beginning balance (in shares) at Dec. 31, 2020	[1]				26,600,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Treasury stock acquired, shares	[1]				(2,100,000)	[2]	(1,000,000.0)
Share-based compensation awards	[3]	(13)			$ 9				(22)	0
Treasury stock acquired	[2]	(347)			(347)
Employee benefit plan contribution from Pfizer Inc.	[4]	1							1
Dividends, Common Stock		(238)								(238)
Ending balance (in shares) at Jun. 30, 2021	[1]		501,900,000
Ending balance at Jun. 30, 2021		4,352	$ 5		$ (2,568)				1,044	6,492	(623)	2
Treasury stock, ending balance (in shares) at Jun. 30, 2021	[1]				27,700,000
Beginning balance (in shares) at Mar. 31, 2021	[1]		501,900,000
Beginning balance at Mar. 31, 2021		4,092	$ 5		$ (2,412)				1,030	6,099	(633)	3
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest		511								512		(1)
Other comprehensive income/(loss), net of tax		10									10
Treasury stock, beginning balance (in shares) at Mar. 31, 2021	[1]				26,900,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Treasury stock acquired, shares	[1]				(1,000,000.0)	[2]	(200,000)
Share-based compensation awards	[3]	24			$ 10				14
Treasury stock acquired	[2]	(166)			(166)
Dividends, Common Stock		(119)								(119)
Ending balance (in shares) at Jun. 30, 2021	[1]		501,900,000
Ending balance at Jun. 30, 2021		$ 4,352	$ 5		$ (2,568)				1,044	6,492	(623)	2
Treasury stock, ending balance (in shares) at Jun. 30, 2021	[1]				27,700,000
Beginning balance (in shares) at Dec. 31, 2021		501,891,243	501,900,000	[1]
Beginning balance at Dec. 31, 2021		$ 4,544	$ 5		$ (2,952)				1,068	7,186	(764)	1
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest		1,123								1,124		(1)
Other comprehensive income/(loss), net of tax		$ 42									42
Treasury stock, beginning balance (in shares) at Dec. 31, 2021		29,317,153			29,300,000	[1]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Treasury stock acquired, shares	[1]				(4,500,000)	[2]	(500,000)
Share-based compensation awards	[3]	$ (12)			$ (2)				(10)
Treasury stock acquired	[2]	(812)			(812)
Employee benefit plan contribution from Pfizer Inc.	[4]	1							1
Dividends, Common Stock		$ (306)								(306)
Ending balance (in shares) at Jun. 30, 2022		501,891,243	501,900,000	[1]
Ending balance at Jun. 30, 2022		$ 4,580	$ 5		$ (3,766)				1,059	8,004	(722)	0
Treasury stock, ending balance (in shares) at Jun. 30, 2022		33,277,795			33,300,000	[1]
Beginning balance (in shares) at Mar. 31, 2022	[1]		501,900,000
Beginning balance at Mar. 31, 2022		$ 4,658	$ 5		$ (3,317)				1,046	7,628	(704)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest		529								529		0
Other comprehensive income/(loss), net of tax		(18)									(18)
Treasury stock, beginning balance (in shares) at Mar. 31, 2022	[1]				30,700,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Treasury stock acquired, shares	[1]				(2,600,000)	[2]	0
Share-based compensation awards	[3]	15			$ 2				13
Treasury stock acquired	[2]	(451)			(451)
Dividends, Common Stock		$ (153)								(153)
Ending balance (in shares) at Jun. 30, 2022		501,891,243	501,900,000	[1]
Ending balance at Jun. 30, 2022		$ 4,580	$ 5		$ (3,766)				$ 1,059	$ 8,004	$ (722)	$ 0
Treasury stock, ending balance (in shares) at Jun. 30, 2022		33,277,795			33,300,000	[1]

[1] Shares may not add due to rounding.

[2] Reflects the acquisition of treasury shares in connection with the share repurchase program. For additional information, see Note 13. Stockholders' Equity.

[3] Includes the issuance of shares of Zoetis Inc. common stock and the reacquisition of shares of treasury stock associated with exercises of employee share-based awards. Also includes the reacquisition of shares of treasury stock associated with the vesting of employee share-based awards to satisfy tax withholding requirements. For additional information, see Note 12. Share-based Payments and Note 13. Stockholders' Equity.

[4] Represents contributed capital from Pfizer Inc. associated with service credit continuation for certain Zoetis Inc. employees in Pfizer Inc.'s U.S. qualified defined benefit and U.S. retiree medical plans.